文献速递银屑病与炎症性皮肤病

spesolimab治疗泛发性脓疱型银屑病发作的随机安慰剂对照Effisayil 1研究中泛发性脓疱型银屑病医师总体评估评分的快速持续改善

Rapid and sustained improvements in Generalized Pustular Psoriasis Physician Global Assessment scores with spesolimab for treatment of generalized pustular psoriasis flares in the randomized, placebo-controlled Effisayil 1 study.
PubMed 文献 · J Am Acad Dermatol · 2023-03-02

Effisayil 1是一项随机安慰剂对照研究,评估spesolimab在泛发性脓疱型银屑病发作患者中的12周疗效。患者(N=53)按2:1随机分配,第1天接受单次静脉900 mg spesolimab或安慰剂,第8天可开放标签使用spesolimab。spesolimab组多数患者第12周达到GPPGA脓疱亚评分0(60.0%)和GPPGA总分0或1(60.0%)。

要点

  • spesolimab组60.0%患者第12周达到GPPGA脓疱亚评分0。
  • spesolimab组60.0%患者第12周达到GPPGA总分0或1。
  • 安慰剂组第8天开放标签spesolimab后GPPGA脓疱亚评分0比例从5.6%升至83.3%。

核心结论

  • spesolimab可快速控制泛发性脓疱型银屑病发作症状并持续12周,进一步支持其作为患者治疗选择的潜力。

研究设计与样本

  • Effisayil 1是一项随机、安慰剂对照研究,纳入泛发性脓疱型银屑病发作患者(N=53),按2:1随机分配,第1天接受单次静脉900 mg spesolimab或安慰剂,第8天可开放标签使用spesolimab。

主要发现

  • spesolimab组60.0%患者第12周达到GPPGA脓疱亚评分0,60.0%患者第12周达到GPPGA总分0或1。
  • 安慰剂组第8天接受开放标签spesolimab的患者中,GPPGA脓疱亚评分0比例从第8天5.6%升至第2周83.3%。
  • 患者人口学或临床特征中未发现可预测spesolimab应答的因素。

关键数值与推荐

  • 主要终点为第1周GPPGA脓疱亚评分0。
  • spesolimab组第12周GPPGA脓疱亚评分0为60.0%,GPPGA总分0或1为60.0%。
  • 安慰剂组开放标签spesolimab后GPPGA脓疱亚评分0从第8天5.6%升至第2周83.3%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 由于患者接受开放标签spesolimab,第1周后无法按常规方法确定初始随机化的效应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Effisayil 1 was a randomized, placebo-controlled study of spesolimab, which is an anti-IL-36 receptor antibody, in patients presenting with a generalized pustular psoriasis flare. OBJECTIVE: To assess the effects of spesolimab over the 12-week study. METHODS: The primary endpoint of the study was Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) pustulation subscore of 0 at week 1. Patients (N = 53) were randomized (2:1) to receive a single intravenous dose of 900 mg spesolimab or placebo on day 1. Patients could receive open-label spesolimab for persistent flare symptoms on day 8. RESULTS: Most patients receiving spesolimab achieved a GPPGA pustulation subscore of 0 (60.0%) and GPPGA total score of 0 or 1 (60.0%) by week 12. In patients randomized to placebo who received open-label spesolimab on day 8, the proportion with GPPGA pustulation subscore of 0 increased from 5.6% at day 8 to 83.3% at week 2. No factors predictive of spesolimab response were identified in patient demographics or clinical characteristics. LIMITATIONS: The effect of initial randomization was not determined conventionally beyond week 1 due to patients receiving open-label spesolimab. CONCLUSION: Rapid control of generalized pustular psoriasis flare symptoms with spesolimab was sustained over 12 weeks, further supporting its potential use as a therapeutic option for patients.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Elewski BE, Lebwohl MG, Anadkat MJ, et al. Rapid and sustained improvements in Generalized Pustular Psoriasis Physician Global Assessment scores with spesolimab for treatment of generalized pustular psoriasis flares in the randomized, placebo-controlled Effisayil 1 study. J Am Acad Dermatol. 2023. PMID: 36870370. doi:10.1016/j.jaad.2023.02.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。